In that study, peripheral administration of monoclonal antibodies that specifically interfere with SEMA3A binding to NRP1 in the same ALS mouse strain used by us improved motor function and significantly increased life span in the ALS-mice. This evidence concerns the gene NRP1 and amyotrophic lateral sclerosis.